The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Huge volume over there this morning and its good to see investors cottoning onto value of Stonechecker and AI. Market continues to ignore us but FDA approval of Stonechecker (using Texrad) is tremendous validation of our technology. It's currently being used in over 50 leading hospitals globally and the work going on at Cambridge with our team will bring commercial success in due course. It was quiet at IQAI for a long time, similar to FDBK and am confident we will follow the upward curve as TO and team begins to deliver. Major shareholders upping their stakes this week is a significant sign of what's in store imho.
Just so!
Not my style to short. Am a long term holder here, met the board in February, regular contact with CEO and 2 largest shareholders increased holdings this week. Comfortable with holding and see it develop.
Interesting update this morning, gives greater sales exposure in USA and therefore benefits Feedback through royalties collected on sales of kidney stones product which uses Texrad and licenced to IQAI. No numbers mentioned but certainly positive for Texrad.
The 2 largest shareholders have increased holdings, after months of concern I think we can relax and wait for next news.
Yes it's TB, appears from time to time to give us a knock. He has appeaed as Regina on other board with same message. We know how he works....
Had contact with TO, review going well and will inform market in due course. Impressed with him, met him in February and has some interesting ideas going forward.
Well said Botak, I agree with your views. Tom has even taken trouble to contact long term shareholders and reiterate his thoughts. He seems to have real class and understands how disenfranchised we have felt in recent times and is very enthusiastic about the future. Look forward to his completed strategic review in due course.
Norfolk boys buying this week in advance of tomorrow's trading update!
Don't panic Mannering it's only 1! Happy Easter everyone.
Agree mate, but we are in their hands, not comfortable at all.
Morning. Equity raise in November was for Sales and Marketing, Cadran development, FDA process and development of relationship with Imaging Endpoints to facilitate entry and growth in USA. I met with all the board including Tom Oakley CEO in Cambridge in February. They gave me 90 minutes and were supremely confident. My key question ' you must realise current business model is not sustainable' (stagnant revenues/ increase cost base )? Response 'we know but cannot divulge information not in public domain, we remain very confident going forward'. The current share price/market capitalization does not reflect the confidence shown by board in February. All the best.
Hi Botak, Justin likes it 'less and less', good grief, when you look at some of the awful stuff he likes and ramps we are not in a good place! Market also likes it less and less, Tom (New CEO), appears in narrative for the first time and we drop 10%. Let's give him a chance and hear what he has to say at Proactive Investors event on the 25th April, can't make it myself but know of a long termer who hopes to attend.
Morning El, have refrained from commenting on football as not in my nature to gloat, especially after last weekend. However, Canaries were similarly placed 12 months ago and with patience and the right appointment am sure QPR will bounce back.
I agree. Options should be in place to reward progress and success, giving away 2% of company for easy target is disappointing. Contrarian view is this stock is so illiquid that CEO could not buy in any quantities without a spike. I hope he makes lots of profit on his options!
Calm down young man, it's a slow burner!! AR being keeping it up his sleeve? Good to see buyers returning, hope they are investors not day traders.
Thanks for all your recent coverage both here and the other board, you are a proper researcher and deserve a publicist role within our company! Seems like waiting for ever for next piece of news but April isn't long to wait now and interested to see how Tom Oakley presents himself to markets.
Mostly sells and some biggies last 3 weeks, since Chairman exuded confidence at my meeting in February. Sadly market doesn't share his optimism and little evidence to arrest the slide currently. Really painful for long term holders.
Received an email from A Riddell, Chairman. Briefly as follows,
- New CEO carried out strategic review of product portfolio
- ambitious plans for growth short, medium and long term
- CEO will present these at Proactive Investors event April 24th
-company will provide trading update at this time with progress report on other outstanding issues
Hope this is seen as useful
Well put and wouldn't disagree with any of that. The narrative style is different to normal and with ECR19 next week it could be start of coordinated PR with decent positive news flow.
'Inflexion points and blue sky'. Confident language isn't it ? Boom boom where's Botak.